Feb. 27, 2023 – The study was further carried out by the Scripps Research Institute in La Jolla, California. They then started human trials for the drug. Their study involved 51 subjects who were assessed over 11 days after they went under treatment with this particular drug.
Barbara Mason, a co-author of the study from the Scripps Research Institute team, told the Oregon Health and Science University Press, “Apremilast’s large effect size on reducing drinking, combined with its good tolerability in our participants, suggests it is an excellent candidate for further evaluation as a novel treatment for people with alcohol use disorder.”
Meanwhile, Mason anticipates that the medication may be even more beneficial for people who are motivated to cut back on their alcohol consumption. The study was conducted with subjects who had alcohol disorders, but were not seeking any kind of treatment.
EMR MATTERS – October 2024 - The challenge is that many in the behavioral health…
TOO LITTLE, TOO LATE? – Dec. 19, 2024 - Assembly Bill 56 (AB 56) proposes…
AND STOPPED DIGGING – Dec. 4, 2024 - In a new interview with The Times,…
NOT JUST IN PENCILS – Dec. 8, 2024 - Americans born before 1966 experienced “significantly…
AS SUCCESSFUL AS EVER – Dec. 3, 2024 - Family Affair actor Johnny Whitaker looked…
ALANON Plus – Dec. 7, 2024 - A high percentage of treatment failures occur due…